-
March 26, 2018PREVIEW
Biogen and AbbVie are voluntarily withdrawing daclizumab, a multiple sclerosis (MS) drug, from the global market, noting concern about the drug’s evolving benefit/risk profile.
... -
June 13, 2017PREVIEW
On June 8, 2017, FDA requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated...
-
January 27, 2017PREVIEW
A District Court judge has ordered Sanofi and Regeneron Pharmaceuticals to take alirocumab (Praluent), a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor, off the U.S. market.
... -
December 5, 2012PREVIEW
The 32-mg single I.V. dose of ondansetron has been pulled from the market, FDA...
-
October 5, 2012PREVIEW
FDA has released an update reporting that Budeprion XL 300 mg is not...
Pages
